Health News
NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies
- Details
- Written by NIH NIH
- Published: 10 June 2018 10 June 2018
Washington, DC - The National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest precision medicine trial of its kind, has achieved a milestone with the release of results from several treatment arms, or sub-studies, of the trial. The new results offer findings of interest for future cancer research that could ultimately play a role in bringing targeted treatments to patients with certain gene abnormalities, regardless of their cancer type.
Presidential Message on Men’s Health Week
- Details
- Written by White House White House
- Published: 09 June 2018 09 June 2018
Washington, DC - Men’s Health Week is an opportunity to raise awareness of the diseases and illnesses that are most prevalent among American men and to reiterate the importance of early detection and preventative health practices. During this week, I encourage all men to evaluate both their mental and physical health and to focus on living a healthy lifestyle.
President Donald J. Trump Provides Resources For Veterans To Get The Care They Deserve From The Doctors They Want
- Details
- Written by White House White House
- Published: 06 June 2018 06 June 2018
Washington, DC - "My pledge to you, our noble warriors, is that my Administration will support you, and your loved ones, and your amazing families every single day, now and always." ~ President Donald J. Trump
Breaking the Silence’ Offers an Inspiring Journey of Healing
- Details
- Written by Linda F. Radke Linda F. Radke
- Published: 07 June 2018 07 June 2018
Chandler, Arizona - Joan Eastman was born like any other girl. However, her life proves to be of great pain. Growing up, she is treated differently by family members, powerless to defend herself against their sexual and psychological abuse.
FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment
- Details
- Written by YNN YNN
- Published: 05 June 2018 05 June 2018
Washington, DC - The U.S. Food and Drug Administration Monday approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.